Described herein is dilute sulfuric acid veterinary grade API intended for incorporation into tablets, injections, capsules, powders, granules, medicated premix, and oral solutions. The material is supplied as an aqueous solution at two concentrations: a 10.0% w/w grade designated in this text as DSA-VET-10 and a 35.0% w/w grade designated DSA-VET-35. The 10.0% w/w solution corresponds to the strength range described by the current United States Pharmacopeia Dilute Sulfuric Acid monograph when the assay is expressed as 9.5–10.5 g/100 mL. The 35.0% w/w grade is a non-compendial industrial concentration that is used where reduced water transport is required in oral premix and granulation operations. In all dosage forms the material acts as a non-volatile pH modifier and sulfate counterion source; its suitability is route-specific because injectable applications impose endotoxin and particulate controls that are not required for every oral premix or granulation use. The same chemical identity does not imply interchangeable use. Injectable application requires low bacterial endotoxin, sub-visible particulate control under USP <788>, and sterile filtration, while an oral premix can tolerate higher bioburden but cannot tolerate elevated chloride because of corrosion and drug-excipient interaction risk.

What Specifications and Test Methods Apply to Injectable and Oral Grades?

The compendial control framework for the 10.0% w/w material is based on titration, density, clarity, impurity limits, and, for parenteral grades, bacterial endotoxins and bioburden. Assay is performed by acid-base titration with carbonate-free sodium hydroxide using a combined pH electrode. The sample is diluted with carbon dioxide-free water and titrated to the second equivalence point near pH 6.8–7.2. Density at 20 °C is measured by oscillating U-tube according to ASTM D4052-22; typical values are 1.0661 g/cm³ for the 10.0% w/w solution and 1.2599 g/cm³ for the 35.0% w/w solution. These values are release checks rather than quantitative assay results. pH is not used as a final release specification for the API because the electrode response is non-linear in concentrated acid, but final product pH is controlled under USP <791>.

Clarity and color are checked against reference suspensions or measured at 430 nm using a spectrophotometer; acceptance is typically no more than 10 NTU for injectable grade, though the specific limit depends on the finished product. Published data for this specific configuration is limited. The 35.0% w/w grade is generally not suitable for direct parenteral use unless the manufacturer performs additional endotoxin reduction, particulate filtration, and batch-specific confirmation. Chloride above 0.005% creates risk of pitting in 316L stainless steel at elevated sterilization temperatures. Iron and heavy metals can catalyze oxidation of antioxidants, vitamins, and unsaturated excipients in premixes and oral solutions; therefore their control is more stringent than in technical-grade acid.

Storage and transfer of the 35.0% w/w material require a ventilated stainless steel or high-density polyethylene system. Because dilution enthalpy is strongly exothermic, the acid must be added to water with continuous agitation; reverse addition may cause localized boiling and acid aerosol. Transfer lines for injectable use are typically 316L stainless steel with internal surface finish Ra ≤0.6 µm per ASME BPE and are passivated before use. Contact with hypochlorite sanitizers, sodium hydroxide, or carbon steel is not permitted because of exothermic reaction or corrosion. Containers should be kept closed at 5–30 °C; at low ambient temperatures, the 10.0% w/w solution may freeze near −2 °C. Opened containers should be retested for density and bioburden before use, particularly when the material will enter injectable processing.

When Tablet Granulation and Powder Blending Require Sulfate Acidification

In tablet manufacturing, the 10.0% w/w acid is often used as a binder-fluid acidulant during wet granulation of weakly basic active substances. It converts the base to a sulfate salt in the granule, which can improve compactability and dissolution rate. The acid is introduced into a high-shear granulator through a peristaltic pump and nozzle at a rate of 2–5 kg/min for a 600 L bowl, but the actual rate is dictated by the formulation’s liquid-to-solid ratio and the main impeller speed. A processing boundary exists at the addition point: if the acid is added without adequate chopper action, local liquid saturation can exceed 0.85 and cause agglomerate growth beyond the target particle size. Batch records from production of buffered veterinary granulations show that acid binder temperature is maintained at 18–22 °C; higher temperatures lower the binder viscosity and change wet mass rheology. Loss on drying is typically controlled to 2.0–3.5% by USP <731> after tray drying at 50–60 °C.

The sulfate counterion is non-volatile, so it remains in the dried granule; this is a deliberate formulation feature but differs from hydrochloric acid, which may be partially lost during drying. Tablet compression on a rotary press may require target hardness 80–120 N; acid granulations containing sulfate salts often show brittle fracture, and precompression force must be adjusted to prevent capping. Disintegration is tested by USP <701>. Use of sulfuric acid in a carbonate-containing formulation is contraindicated because sulfate reacts with carbonate to generate carbon dioxide, causing loss of granule integrity and variable tablet mass. For water-sensitive actives, the 35.0% w/w grade permits lower water addition, but the higher acid strength demands closer control of nozzle atomization to avoid localized charring of starch, cellulose, or maltodextrin binders.

For oral powders, granules, medicated premix, and capsules, the acid is typically sprayed onto a silica or maltodextrin carrier in a ribbon blender with 316L contact surfaces. Calcium carbonate carriers are not used because sulfate reacts to form calcium sulfate and carbon dioxide, causing caking and loss of flow. Mixing time is determined by uniformity testing; a typical sampling plan uses 10 thief probe samples and relative standard deviation ≤5.0% for acid content. In liquid-filled hard capsules, the acid is used at low concentration in a non-aqueous vehicle after compatibility evaluation at 40 °C/75% RH for 6 months; published data for this specific configuration is limited. Oral solutions are usually adjusted to pH 2.5–4.0 with USP <791> verification; the acid is fed through a static mixer using a proportional pH control loop to avoid overshoot. Injectable forms use the 10.0% w/w grade only when the intended active is compatible with sulfate. A typical sequence for a small-volume parenteral is: dissolve the active in Water for Injection, add the acid through a dip tube with agitation at 150–250 rpm, adjust pH to the target range, then add tonicity agent and dilute to final volume. The solution is filtered through 0.22 µm membrane filters before filling and sterilized by terminal steam sterilization or aseptic filtration. The non-volatile character of sulfuric acid prevents pH drift during terminal steam cycles in vented vessels; this is a key process advantage over hydrochloric acid.

Compatibility Boundaries and Comparative Acidulant Selection

The primary operational boundary is sulfate precipitation. Calcium sulfate has limited solubility in water; published solubility for gypsum at 20 °C is approximately 2.5 g/L, but the value is reduced by ethanol or polyols present in some parenteral vehicles. Consequently, dilution and mixing orders must be fixed, and the maximum hold time before filtration should be validated; a common in-process limit is 2 hours when calcium is present. The second boundary is materials of construction. Dilute sulfuric acid corrodes carbon steel and can attack 304 stainless steel at elevated temperatures; for injectable processing, 316L, PVDF, PFA, and borosilicate glass are accepted contact materials. Elastomeric seals should be ethylene propylene diene monomer or silicone; natural rubber can deteriorate rapidly at pH below 1.0.

Compared with hydrochloric acid, dilute sulfuric acid has lower vapor pressure and does not build chloride stress-corrosion conditions in 316L autoclaves. Compared with phosphoric acid, it provides stronger initial pH depression per unit volume but less buffering near neutral pH. Compared with citric acid, it leaves no organic carbon source and therefore reduces the risk of microbial spoilage in oral solutions; however, citrate is preferred when calcium-containing formulations require chelation. The specification difference between veterinary API grade and technical-grade sulfuric acid is not concentration alone. Technical material may contain iron, chloride, and suspended solids that interfere with titration endpoints, catalyze oxidation of vitamins or antioxidants in premixes, and generate visible particles in injectable solutions. The absence of endotoxin testing in technical grades makes them unsuitable for parenteral or ophthalmic preparations. Published data for this specific veterinary-grade configuration is limited, but the quality burden is higher because the material enters the drug product rather than a cleaning or pH-neutralization operation.